Merck (MSD outside of the US and Canada) has entered into an exclusive global license agreement with Chinese biopharmaceutical company Hansoh Pharma for its investigational oral GLP-1 receptor agonist, HS-10535. The deal grants Merck rights to develop, manufacture, and commercialize the compound, while Hansoh Pharma will receive an upfront payment of $112 million and up to $1.9 billion in milestone payments.
According to Merck Research Laboratories President Dr. Dean Y. Li, the company aims to build on its experience targeting incretin biology to evaluate HS-10535’s potential for providing additional cardiometabolic benefits beyond weight reduction. The agreement also includes a pre-tax charge of $112 million for Merck.
Hansoh Pharma Executive Director Eliza Sun stated that the in-license of HS-10535 by Merck marks an opportunity for the company to accelerate the development of this promising asset for patients worldwide, leveraging Merck’s expertise and capabilities.
The deal highlights Merck’s focus on science-driven business development and its commitment to exploring innovative solutions for cardiometabolic diseases.
Source: https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-with-hansoh-pharma-for-investigational-oral-glp-1-receptor-agonist